AstraZeneca’s Imfinzi combination shows positive results in phase 3 liver cancer study
About 75% of all primary liver cancers in adults are HCC and up to 30% of HCC patients are eligible for embolisation
About 75% of all primary liver cancers in adults are HCC and up to 30% of HCC patients are eligible for embolisation
Submission to be reviewed under FDA real-time oncology review and Project Orbis
Keynote -564 is the first Phase 3 trial to demonstrate superior overall survival (OS) with adjuvant therapy compared to placebo in patients with RCC
Aarti Drugs has reported total income of Rs. 607.61 crores during the period ended December 31, 2023
He is a former Neurology faculty member at The Johns Hopkins Hospital and an elected Fellow of the Royal College of Physicians, United Kingdom
Denifanstat achieved statistically significant results on primary and multiple secondary endpoints in a 52-week clinical trial
Granules India has reported total income of Rs. 1156.23 crores during the period ended December 31, 2023
Growth team leads financing round in Cleveland Diagnostics; company to advance novel blood-based diagnostic technology to improve and lower costs for patients with cancer
Produodopa is the first-and-only subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of severe motor fluctuations
The bold, dynamic, and new logo unveiled in this process captures the essence of the 'Better Together' theme
Subscribe To Our Newsletter & Stay Updated